NCT01570998 is a NA clinical trial of Intraoperative Radiation Therapy in Stage IA Breast Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT01570998?

NCT01570998 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT01570998?

Interventions in NCT01570998: Intraoperative Radiation Therapy, Laboratory Biomarker Analysis.

What condition does NCT01570998 study?

NCT01570998 studies Stage IA Breast Cancer, Stage IIA Breast Cancer.

Is NCT01570998 still recruiting?

NCT01570998 is currently active, enrolled. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT01570998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Active, enrolled NA Last updated 18 March 2026

What this trial tests

NA trial testing Intraoperative Radiation Therapy in Stage IA Breast Cancer in 1,259 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 May 2012

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1,259
Start date	18 May 2012
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	25 locations across United States

Drugs / interventions tested

Intraoperative Radiation Therapy
Laboratory Biomarker Analysis — full drug profile →

Conditions studied

Stage IA Breast Cancer — all drugs for Stage IA Breast Cancer →
Stage IIA Breast Cancer — all drugs for Stage IIA Breast Cancer →

Sponsor

University of California, San Francisco

Who can join

45 and older, female only, with Stage IA Breast Cancer or Stage IIA Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Dosimetric evaluation of incorporating the revised V4.0 calibration protocol for breast intraoperative radiotherapy with the INTRABEAM system.
Shaikh MY, Burmeister J, Scott R, Kumaraswamy LK, et al · · 2020 · cited 8× · PMID 32039545 · DOI 10.1002/acm2.12807
Update on intraoperative radiotherapy: new challenges and issues.
Esposito E, Douek M. · · 2018 · cited 8× · PMID 29434659 · DOI 10.3332/ecancer.2018.793

Verify or expand the search:

Other trials of Intraoperative Radiation Therapy

Trials testing the same drug.

NCT04754321 — Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer · Phase 1 · recruiting
NCT04595435 — IORT-Breast at Medical Center Navicent Health · active not recruiting

Other recruiting trials for Stage IA Breast Cancer

Currently open trials in the same condition.

NCT05318274 — Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. · NA · active not recruiting
NCT02927912 — Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery Wi · Phase 2 · active not recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01570998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01570998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing